635 related articles for article (PubMed ID: 26223941)
1. Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.
Iturrino J; Camilleri M; Acosta A; O'Neill J; Burton D; Edakkanambeth Varayil J; Carlson PJ; Zinsmeister AR; Hurt R
JPEN J Parenter Enteral Nutr; 2016 Nov; 40(8):1089-1095. PubMed ID: 26223941
[TBL] [Abstract][Full Text] [Related]
2. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
Jeppesen PB; Sanguinetti EL; Buchman A; Howard L; Scolapio JS; Ziegler TR; Gregory J; Tappenden KA; Holst J; Mortensen PB
Gut; 2005 Sep; 54(9):1224-31. PubMed ID: 16099790
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
[TBL] [Abstract][Full Text] [Related]
4. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
Jeppesen PB; Pertkiewicz M; Messing B; Iyer K; Seidner DL; O'keefe SJ; Forbes A; Heinze H; Joelsson B
Gastroenterology; 2012 Dec; 143(6):1473-1481.e3. PubMed ID: 22982184
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.
Thymann T; Stoll B; Mecklenburg L; Burrin DG; Vegge A; Qvist N; Eriksen T; Jeppesen PB; Sangild PT
J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):694-702. PubMed ID: 24399211
[TBL] [Abstract][Full Text] [Related]
6. A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients.
Naimi RM; Madsen KB; Askov-Hansen C; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
Regul Pept; 2013 Jun; 184():47-53. PubMed ID: 23501043
[TBL] [Abstract][Full Text] [Related]
7. Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide-9 Years of Follow-Up.
Zaczek Z; Jurczak-Kobus P; Panczyk M; Braszczyńska-Sochacka J; Majewska K; Kunecki M; Dąbrowska K; Sobocki J
Nutrients; 2022 Apr; 14(8):. PubMed ID: 35458196
[TBL] [Abstract][Full Text] [Related]
8. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B; O'Keefe SJ
Gut; 2011 Jul; 60(7):902-14. PubMed ID: 21317170
[TBL] [Abstract][Full Text] [Related]
9. Comparing the Intestinotrophic Effects of 2 Glucagon-Like Peptide-2 Analogues in the Treatment of Short-Bowel Syndrome in Neonatal Piglets.
Pauline ML; Nation PN; Wizzard PR; Hinchliffe T; Wu T; Dimitriadou V; Turner JM; Wales PW
JPEN J Parenter Enteral Nutr; 2021 Mar; 45(3):538-545. PubMed ID: 32437048
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study.
Madsen KB; Askov-Hansen C; Naimi RM; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
Regul Pept; 2013 Jun; 184():30-9. PubMed ID: 23511332
[TBL] [Abstract][Full Text] [Related]
11. Complementary and antagonistic effects of combined glucagon-like peptide-2 and glucagon-like peptide-1 receptor agonist administration on parameters relevant to short bowel syndrome.
Srikrishnaraj A; Jeong H; Brubaker PL
JPEN J Parenter Enteral Nutr; 2022 Aug; 46(6):1361-1370. PubMed ID: 34826336
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.
Jeppesen PB; Hartmann B; Thulesen J; Graff J; Lohmann J; Hansen BS; Tofteng F; Poulsen SS; Madsen JL; Holst JJ; Mortensen PB
Gastroenterology; 2001 Mar; 120(4):806-15. PubMed ID: 11231933
[TBL] [Abstract][Full Text] [Related]
13. Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study.
Seidner DL; Fujioka K; Boullata JI; Iyer K; Lee HM; Ziegler TR
Nutr Clin Pract; 2018 Aug; 33(4):520-527. PubMed ID: 29761915
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
Jeppesen PB; Gabe SM; Seidner DL; Lee HM; Olivier C
Gastroenterology; 2018 Mar; 154(4):874-885. PubMed ID: 29174926
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome.
Jeppesen PB
JPEN J Parenter Enteral Nutr; 2014 May; 38(1 Suppl):45S-52S. PubMed ID: 24615689
[TBL] [Abstract][Full Text] [Related]
16. Experience with teduglutide treatment for short bowel syndrome in clinical practice.
Pevny S; Maasberg S; Rieger A; Karber M; Blüthner E; Knappe-Drzikova B; Thurmann D; Büttner J; Weylandt KH; Wiedenmann B; Müller VA; Bläker H; Pascher A; Pape UF
Clin Nutr; 2019 Aug; 38(4):1745-1755. PubMed ID: 30145039
[TBL] [Abstract][Full Text] [Related]
17. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
Wismann P; Pedersen SL; Hansen G; Mannerstedt K; Pedersen PJ; Jeppesen PB; Vrang N; Fosgerau K; Jelsing J
Physiol Behav; 2018 Aug; 192():72-81. PubMed ID: 29540315
[TBL] [Abstract][Full Text] [Related]
18. Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.
Naberhuis JK; Tappenden KA
JPEN J Parenter Enteral Nutr; 2016 Nov; 40(8):1096-1105. PubMed ID: 25883117
[TBL] [Abstract][Full Text] [Related]
19. Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome.
Lim DW; Levesque CL; Vine DF; Muto M; Koepke JR; Nation PN; Wizzard PR; Li J; Bigam DL; Brubaker PL; Turner JM; Wales PW
Am J Physiol Gastrointest Liver Physiol; 2017 Apr; 312(4):G390-G404. PubMed ID: 28104586
[TBL] [Abstract][Full Text] [Related]
20. Increased intestinal permeability in patients with short bowel syndrome is not affected by parenteral nutrition.
Cinkajzlová A; Lacinová Z; Kloučková J; Kaválková P; Kratochvílová H; Křížová J; Trachta P; Mráz M; Haluzík M
Physiol Res; 2019 Oct; 68(5):817-825. PubMed ID: 31424246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
